Bristol-myers Squibb Compnay

E. R. Squibb Sons, Inc.

Other

Bristol Meyers Squibb Company

Sher, Philip Michael

Philip Michael Sher

Gang Wu

William N Washburn

Bruce A Ellsworth

Steven E Hall

William R Ewing

Wei Meng

Chongqing Sun

Natesan Murugesan

Raj N Misra

Philip D Stein

Kathleen M Poss

Amarendra B Mikkilineni

Joel C Barrish

David M Floyd

Yanting Huang

Terry Stouch

Jagabandhu Das

Ashvinikumar V Gavai

Annapurna Pendri

Richard B Sulsky

Gregory S Bisacchi

Guixue Yu

Samuel Gerritz

Zhengxiang Gu

Alexandra A Nirschl

Ximao Wu

Arvind Mathur

Ying Wang

Katerina Leftheris

Chunjian Liu

Stephen T Wrobleski

Richard H Mueller

Taekyu Lee

Denis E Ryono

Jollie D Godfrey, Jr

Janak Singh

Wen-Ching Han

Laxman Pasunoori

Yeheng Zhu

John J Venit

Peter T Cheng

Doree F Sitkoff

Chong-qing Sun

Maheswaran Sivasamban Karatholuvhu

Ambarish K Singh

Shankar Swaminathan

Scott A Bolton

Sunil Kumar Mandal

Wen-sen Li

Wllliam N Washburn

Stephen R Johnson

Ravindar N Girotra

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are agonists, partial agonists and modulators of the NPY Y4 receptor and may be used for the treatment and prophylaxis of various diseases and conditions.

Diaminocyclohexane compounds and uses thereof

Embodiments of the invention are devices for assisting users in the management of blood glucose concentration levels in patients. Devices of the invention provide users with detailed information related to the pharmacodynamic behavior of insulin in a patient. By displaying and accepting information concerning time-dependent rates and amounts of pharmacodynamic insulin unit equivalents, the devices of the invention empower the user to make effective decisions regarding insulin dosing.

Device for predicting and managing blood glucose by analyzing the effect of, and controlling, pharmacodynamic insulin equivalents

Indole indane amides which are CB2 agonists are provided which have the structure wherein R, R, R, Rand Rare as defined herein, which compounds are useful in treating autoimmune diseases, inflammation, pain, cardiovascular disorders and other diseases mediated by CB2 receptors. A method for preventing or treating such diseases employing the compounds of the invention is also provided.

Indole indane amide compounds useful as CB2 agonists and method

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I. including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R, R, R, R, R, m and n are described herein.

Azabicyclic heterocycles as cannabinoid receptor modulators

Embodiments of the present invention provide a new system and methods for monitoring blood glucose concentration. A user of a continuous glucose monitor may program upper and lower blood glucose notification thresholds to fluctuate over time in order to facilitate management of the short-term effects of food consumption, insulin delivery aberrations, physical activity, emotions, and unforeseen circumstances.

Fluctuating blood glucose notification threshold profiles and methods of use

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R, R, R, Rand Rare described herein.

Triazolopyridine cannabinoid receptor 1 antagonists

The present application describes compounds according to Formula I, wherein R, R, R, R, X and Y are described herein. Additionally, the present application describes pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents. Finally, the present application describes methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. 

N-sulfonylpiperidine cannabinoid receptor 1 antagonists

The present application describes compounds according to both Formulas I and II, pharmaceutical compositions comprising at least one compound according to either Formula I or II and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formulas I and II both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formulas: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R, R, R, Rand Rare described herein.

Triazolopyrimidine cannabinoid receptor 1 antagonists

A compound of formula I is provided having the structure wherein Further provided is a method for treating diabetes and related diseases employing the above compound, either alone or in combination with another therapeutic agent.

Lactam glycogen phosphorylase inhibitors and method of use

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R, R, R, R, R, m and n are described herein.

Novel compounds are provided which are glycogen phosphorylase inhibitors which are useful in treating, preventing or slowing the progression of diseases requiring glycogen phosphorylase inhibitor therapy such as diabetes and related conditions (such as hyperglycemia, impaired glucose tolerance, insulin resistance and hyperinsulinemia), the microvascular complications associated with diabetes (such as retinopathy, neuropathy, nephropathy and delayed wound healing), the macrovascular complications associated with diabetes (cardiovascular diseases such as atherosclerosis, abnormal heart function, myocardial ischemia and stroke), as well as Metabolic Syndrome and its component conditions including hypertension, obesity and dislipidemia (including hypertriglyceridemia, hypercholesterolemia and low HDL), and other maladies such as non-cardiac ischemia, infection and cancer. These novel compounds have the structure or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, R, R, X, Y and Z are defined herein.

2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors

The invention provides for compounds of formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of eating disorders, metabolic disorders, obesity, cognitive disorders, neurological disorders, pain disorders, inflammation disorders, in the promotion of smoking cessation and for the treatment of other psychiatric disorders Also provided are pharmaceutical compositions containing such compounds and pharmaceutical combinations of the compounds of the invention with other therapeutic agents.

Tetrahydroquinoline derivatives as cannabinoid receptor modulators

Novel compounds are provided which are glycogen phosphorylase inhibitors which are useful in treating, preventing or slowing the progression of diseases requiring glycogen phosphorylase inhibitor therapy such as diabetes and related conditions (such as hyperglycemia, impaired glucose tolerance, insulin resistance and hyperinsulinemia), the microvascular complications associated with diabetes (such as retinopathy, neuropathy, nephropathy and delayed wound healing), the macrovascular complications associated with diabetes (cardiovascular diseases such as atherosclerosis, abnormal heart function, myocardial ischemia and stroke), as well as Metabolic Syndrome and its component conditions including hypertension, obesity and dislipidemia (including hypertriglyceridemia, hypercholesterolemia and low HDL), and other maladies such as non-cardiac ischemia, infection and cancer. These novel compounds have the structure or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, R, R, X and Z are defined herein.

2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors

Novel compounds are provided which are glycogen phosphorylase inhibitors which are useful in treating, preventing or slowing the progression of diseases requiring glycogen phosphorylase inhibitor therapy such as diabetes and related conditions (such as hyperglycemia, impaired glucose tolerance, insulin resistance and hyperinsulinemia), the microvascular complications associated with diabetes (such as retinopathy, neuropathy, nephropathy and delayed wound healing), the macrovascular complications associated with diabetes (cardiovascular diseases such as atherosclerosis, abnormal heart function, myocardial ischemia and stroke), as well as Metabolic Syndrome and its component conditions including hypertension, obesity and dislipidemia (including hypertriglyceridemia, hypercholesterolemia and low HDL), and other maladies such as non-cardiac ischemia, infection and cancer. These novel compounds have the structure or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, Rand Rare defined herein.

2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors

Novel compounds are provided which are glycogen phosphorylase inhibitors which are useful in treating, preventing or slowing the progression of diseases requiring glycogen phosphorylase inhibitor therapy such as diabetes and related conditions (such as hyperglycemia, impaired glucose tolerance, insulin resistance and hyperinsulinemia), the microvascular complications associated with diabetes (such as retinopathy, neuropathy, nephropathy and delayed wound healing), the macrovascular complications associated with diabetes (cardiovascular diseases such as atherosclerosis, abnormal heart function, myocardial ischemia and stroke), as well as Metabolic Syndrome and its component conditions including hypertension, obesity and dislipidemia (including hypertriglyceridemia, hypercholesterolemia and low HDL), and other maladies such as non-cardiac ischemia, infection and cancer. These novel compounds have the structure or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, R, R, Y and Z are defined herein.

2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors

Growing community of inventors

Plainsboro, NJ, United States of America

Philip Michael Sher